Treatment considerations for the management of fibrodysplasia ossificans progressiva

被引：38

作者：

Glaser D.L. ^{[1
,3
]}

Kaplan F.S. ^{[1
,2
,3
,4
]}

机构：

[1] Department of Orthopaedic Surgery, University of Pennsylvania, School of Medicine, Philadelphia, PA

[2] Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA

[3] Center for Research in FOP and Related Disorders, University of Pennsylvania, School of Medicine, Philadelphia, PA

[4] Department of Orthopaedic Surgery, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, Silverstein Two

来源：

Clinical Reviews in Bone and Mineral Metabolism | 2005年 / 3卷 / 3-4期

关键词：

Fibrodysplasia ossificans progressiva (FOP); Pathophysiology; Treatment guidelines;

D O I：

10.1385/BMM:3:3-4:243

中图分类号：

学科分类号：

摘要：

The ultimate goal of research on fibrodysplasia ossificans progressiva (FOP) is the development of treatments that will prevent, halt, or even reverse the progression of the condition. Despite advances in understanding the pathophysiology of FOP, there are no therapies with scientifically proven benefits for the prevention or treatment of FOP. Insights obtained from the research laboratory and from the treatment of hundreds of patients worldwide have allowed us to identify targets for potential therapies. Some of these therapies involve the use of currently available medications, whereas others involve novel therapeutic approaches that are in preclinical testing. In this article, we will review the scientific basis for considering various therapeutic options based on the known pathophysiology of FOP. Because there are presently no proven preventions or treatments for the condition, this article is intended to represent an opinion of the authors that may be helpful to others who face similar situations. © Copyright 2005 by Humana Press Inc. All rights of any nature whatsoever reserved.

引用

页码：243 / 250

页数：7

共 51 条

[1]

Glaser D.L., Economides A.N., Wang L., Et al., In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification, J Bone Joint Surg Am, 12, pp. 2332-2342, (2003)

[2]

Kan L., Hu M., Gomes W.A., Kessler J.A., Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype, Am J Pathol, 165, pp. 1107-1115, (2004)

[3]

Connor J.M., Evans D.A., Fibrodysplasia ossificans progressiva (FOP): The clinical features and natural history of 34 patients, J Bone Joint Surg Br, 64, pp. 76-83, (1982)

[4]

Connor J.M., Fibrodysplasia ossificans progressiva - Lessons from rare maladies, N Engl J Med, 335, pp. 591-593, (1996)

[5]

Delatycki M., Rogers J.G., The genetics of fibrodysplasia ossificans progressiva, Clin Orthop, 346, (1998)

[6]

Kaplan F.S., Delatycki M., Gannon F.H., Rogers J.G., Smith R., Shore E.M., Fibrodysplasia ossificans progressiva, Neuromuscular Disorders: Clinical and Molecular Genetics, pp. 289-321, (1998)

[7]

Kaplan F.S., Shore E.M., Connor J.M., Fibrodysplasia ossificans progressiva (FOP), Connective Tissue and Its Heritable Disorders, pp. 827-840, (2002)

[8]

Kaplan F.S., Glaser D.L., Shore E.M., The fourteenth annual report of the fibrodysplasia ossificans progressiva (FOP) collaborative research project, FOP Connection, 16, 2, pp. 1-20, (2005)

[9]

Xu M.-Q., Feldman G., Le Merrer M., Et al., Linkage exclusion and mutational analysis of the Noggin gene in patients with fibrodysplasia ossificans progressiva, Clin Genet, 58, pp. 291-298, (2000)

[10]

Kaplan F.S., Glaser D.L., Shore E.M., Fibrodysplasia (myositis) ossificans progressiva, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th Ed., pp. 513-516, (2003)

← 1 2 3 4 5 6 →